Did you know the pharmacogenomics market is projected to hit $10.68 billion by 2033? With a growth rate of nearly 10% annually, this field is transforming how healthcare operates. Major players like Thermo Fisher Scientific and Abbott Laboratories already dominate 22% of the market. But how can businesses capitalize beyond one-time tests? Let's discuss Recurring Revenue in Pharmacogenomics.
Business woman hand with Financial charts and laptop on the table
Today, 68% of leading hospitals integrate pharmacogenomic testing into routine diagnostics. The shift from single-use tests to subscription models unlocks long-term value. Advanced PCR, sequencing, and AI-driven analytics make this possible.
North America leads in adopting personalized medicine, with precision medicine reshaping treatment plans. The question isn’t just about testing—it’s about sustaining engagement. How can your strategy evolve with this booming industry?
Introductio...
_____
If you are a member of our Association, please log in below to continue reading our exclusive content.
Not a member yet? Discover the benefits of joining our network and gain access to exclusive content like this for only $29.95 per month. Learn More and Sign Up
